Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of iparomlimab + tuvonralimab with lenvatinib as perioperative therapy for resectable hepatocellular carcinoma
ChiCTR2600128289Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Major Pathological Response Rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600128289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128289.